Teladoc Health Inc (NYSE:TDOC) posted upbeat results for the fourth quarter on Wednesday.

The company posted a quarterly loss of 14 cents per share, versus market estimates of a loss of 18 cents per share. The company's sales came in at $642.269 million, beating estimates of $635.235 million.

Teladoc Health said it sees FY2026 GAAP loss of $(1.10)-$(0.70) vs market estimates of $(0.76). The company expects sales of $2.470 billion-$2.587 billion, versus estimates of $2.548 billion.

“We closed 2025 with a solid finish, delivering consolidated revenue and adjusted EBITDA above the midpoint of our guidance ranges for the fourth quarter. I’m encouraged by the progress we made last year against each of our strategic priorities, as we strengthened our product portfolio, advanced innovation across Integrated Care and BetterHelp, and positioned the company to build on this momentum in 2026,” said Chuck Divita, Chief Executive Officer of Teladoc Health.

Teladoc Health shares gained 13.5% to trade at $5.28 on Thursday.

• These analysts made changes to their price targets on Teladoc Health following earnings announcement.
• Stifel analyst David Grossman maintained Teladoc Health with a Hold and lowered the price target from $8 to $6.
• Wells Fargo analyst Stan Berenshteyn maintained the stock with an Equal-Weight rating and cut the price target from $8 to $6.
• Evercore ISI Group analyst Elizabeth Anderson maintained Teladoc Health with an In-Line rating and lowered the price target from $8 to $5.
• Piper Sandler analyst Jessica Tassan reiterated Teladoc Health with an Overweight rating and lowered the price target from $12 to $9.
• BMO Capital analyst Sean Dodge maintained Teladoc Health with a Market Perform and lowered the price target from $8 to $5.
• TD Cowen analyst Charles Rhyee maintained the stock with a Hold and lowered the price target from $8 to $6.

Considering buying TDOC stock? Here’s what analysts think:

Photo via Shutterstock